Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by ⁸⁹Zr Immuno-PET

Figure 3

⁸⁹Zr-CD133 IgG biodistribution and PET in mice. (a) Time-dependent blood clearance of ⁸⁹Zr-CD133 IgG following intravenous injection in normal Balb/c mice (left) and 6-day biodistribution in HT29 tumor-bearing Balb/c nu mice with or without excess cold anti-CD133 IgG (right). The blood clearance curve was fitted with two-phase exponential decay nonlinear regression to obtain early and late rate constants (K1 and K2) and half-lives (T1/2α and T1/2β). (b) Representative maximal intensity projection (left) and coronal (middle) and transaxial (right) PET images at 6 days postinjection in tumor-bearing mice with or without excess cold IgG. (c) PET image-based tumor uptake level (left) and correlation between PET image-based and ex vivo count-based tumor uptake levels (right). All data are of %ID/g obtained from five (blood clearance) or three mice per group (biodistribution and PET). , ^†, compared to tumor uptake in the absence of excess cold IgG.

(a)

(b)

(c)